ArticleHemaSphere2022

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.

Paolo Ghia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.